The synthesis of selectively oxidized cellulose, 2,3-dicarboxycellulose (DCC), is optimized for preparation of highly oxidized material for biological applications, which includes control over the molecular weight of the product during its synthesis. Conjugates of DCC and cisplatin simultaneously offer a very high drug binding efficiency (>90%) and drug loading capacity (up to 50 wt %), while retaining good aqueous solubility. The adjustable molecular weight of the DCC together with variances in drug feeding ratio allows to optimize cisplatin release profiles from delayed (<2% of cisplatin released during 6 h) to classical burst release with more than 60% of cisplatin released after 24 h. The release rates are also pH-dependent (up to 2 times faster release at pH 5.5 than at pH 7.4), which allows to exploit the acidic nature of tumor microenvironment. Extensive in vitro studies were performed on eight different cell lines for two cisplatin-DCC conjugates with different release profiles. In comparison with free cisplatin, both cisplatin-DCC conjugates demonstrated considerably lower cytotoxicity toward healthy cells. Conjugates with burst release profiles were found more effective against prostate cell lines, while DCC conjugates with slower release were more cytotoxic against ovarian and lung carcinoma cell lines. In vivo studies indicated a significantly longer survival rate, a reduction in tumor volume, and a higher accumulation of platinum in tumors of mice treated with the cisplatin-DCC conjugate in comparison to those treated by free cisplatin.

BIOCEV 1st Faculty of Medicine Charles University Průmyslová 595 252 50 Vestec Czech Republic

Centre of Polymer Systems Tomas Bata University in Zlín tř Tomáše Bati 5678 760 01 Zlín Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc20022781

003      

CZ-PrNML

005      

20201214124803.0

007      

ta

008      

201125s2019 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1021/acs.biomac.8b01807 $2 doi

035    __

$a (PubMed)30794396

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Münster, Lukáš $u Centre of Polymer Systems , Tomas Bata University in Zlín , tř. Tomáše Bati 5678 , 760 01 Zlín , Czech Republic.

245    10

$a Selectively Oxidized Cellulose with Adjustable Molecular Weight for Controlled Release of Platinum Anticancer Drugs / $c L. Münster, M. Fojtů, Z. Capáková, T. Vaculovič, M. Tvrdoňová, I. Kuřitka, M. Masařík, J. Vícha,

520    9_

$a The synthesis of selectively oxidized cellulose, 2,3-dicarboxycellulose (DCC), is optimized for preparation of highly oxidized material for biological applications, which includes control over the molecular weight of the product during its synthesis. Conjugates of DCC and cisplatin simultaneously offer a very high drug binding efficiency (>90%) and drug loading capacity (up to 50 wt %), while retaining good aqueous solubility. The adjustable molecular weight of the DCC together with variances in drug feeding ratio allows to optimize cisplatin release profiles from delayed (<2% of cisplatin released during 6 h) to classical burst release with more than 60% of cisplatin released after 24 h. The release rates are also pH-dependent (up to 2 times faster release at pH 5.5 than at pH 7.4), which allows to exploit the acidic nature of tumor microenvironment. Extensive in vitro studies were performed on eight different cell lines for two cisplatin-DCC conjugates with different release profiles. In comparison with free cisplatin, both cisplatin-DCC conjugates demonstrated considerably lower cytotoxicity toward healthy cells. Conjugates with burst release profiles were found more effective against prostate cell lines, while DCC conjugates with slower release were more cytotoxic against ovarian and lung carcinoma cell lines. In vivo studies indicated a significantly longer survival rate, a reduction in tumor volume, and a higher accumulation of platinum in tumors of mice treated with the cisplatin-DCC conjugate in comparison to those treated by free cisplatin.

650    _2

$a zvířata $7 D000818

650    12

$a antitumorózní látky $x chemie $x farmakokinetika $x farmakologie $7 D000970

650    12

$a celulosa $x chemie $x farmakokinetika $x farmakologie $7 D002482

650    12

$a cisplatina $x chemie $x farmakokinetika $x farmakologie $7 D002945

650    _2

$a léky s prodlouženým účinkem $x chemie $x farmakokinetika $x farmakologie $7 D003692

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a lidé $7 D006801

650    _2

$a koncentrace vodíkových iontů $7 D006863

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a myši $7 D051379

650    _2

$a buňky NIH 3T3 $7 D041681

650    12

$a nádory $x farmakoterapie $x metabolismus $x patologie $7 D009369

650    _2

$a oxidace-redukce $7 D010084

650    _2

$a buňky PC-3 $7 D000078722

650    _2

$a nádorové mikroprostředí $x účinky léků $7 D059016

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Fojtů, Michaela

700    1_

$a Capáková, Zdenka $u Centre of Polymer Systems , Tomas Bata University in Zlín , tř. Tomáše Bati 5678 , 760 01 Zlín , Czech Republic.

700    1_

$a Vaculovič, Tomáš

700    1_

$a Tvrdoňová, Michaela

700    1_

$a Kuřitka, Ivo $u Centre of Polymer Systems , Tomas Bata University in Zlín , tř. Tomáše Bati 5678 , 760 01 Zlín , Czech Republic.

700    1_

$a Masařík, Michal $u BIOCEV, First Faculty of Medicine , Charles University , Průmyslová 595 , 252 50 Vestec , Czech Republic.

700    1_

$a Vícha, Jan $u Centre of Polymer Systems , Tomas Bata University in Zlín , tř. Tomáše Bati 5678 , 760 01 Zlín , Czech Republic.

773    0_

$w MED00006456 $t Biomacromolecules $x 1526-4602 $g Roč. 20, č. 4 (2019), s. 1623-1634

856    41

$u https://pubmed.ncbi.nlm.nih.gov/30794396 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20201125 $b ABA008

991    __

$a 20201214124803 $b ABA008

999    __

$a ok $b bmc $g 1595100 $s 1113457

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2019 $b 20 $c 4 $d 1623-1634 $e 20190307 $i 1526-4602 $m Biomacromolecules $n Biomacromolecules $x MED00006456

LZP    __

$a Pubmed-20201125